Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...

Optas LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 7.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,232.95 today based on a ...

AbbVie, Eli Lilly and Company, Vertex Pharmaceuticals, Thermo Fisher Scientific, and Johnson & Johnson are the five ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...